A welcome letter from the EU-IPFF President

Dear Friends and Colleagues,

It is with immense pleasure to invite you to Warsaw for the first European IPF Patient Summit. Warsaw is not only the capital of Poland, it is also one of the leading economic, cultural, industrial, educational, medical and technological centres of Eastern Europe, making it the ideal venue for our first European IPF Patient Summit.

Poland has been a knowledge hub for centuries – it was here that Maria Skłodowska-Curie (1867-1934) became active in her research on radioactivity. During World War I, she organised mobile diagnostic units equipped with x-ray machines that helped to diagnose thousands of wounded soldiers. To this day, Skłodowska-Curie remains the only woman to receive two Nobel Prizes. In addition, Zbigniew Religa (1938-2009), a world-class cardiac surgeon and Minister of Health from 2005 to 2007, was a pioneer in human heart transplantation in Poland. In 2004, he, together with his team, obtained a prestigious “Brussels Eureka” award at the World Exhibition of Innovation, Research and Technology for developing an implantable pump for a pneumatic heart assistance system. It does not stop here. From scientists and astronomers, to musicians, artists and the Pope – Poland has a lot to offer.

Due to this innovative environment, often ahead of the times, it became clear to us that Warsaw was the perfect place host the first European patient summit in the field of IPF and ILDs. It is a great honour to be part of the first European IPF Patient Summit, whereby patient-centricity and involvement are the top priorities.

After years of attending global congresses, where world-class healthcare professionals,leading pharmaceuticals and pioneering researchers present their latest findings, we foundthat the patient perspective was often over-looked. This is what we at the European Idiopathic Pulmonary Fibrosis and other Related Disorders Federation (EU-IPFF) wanted to change. We believe that patients need to be incorporated at every stage of research, from disease, to treatment, and throughout the care pathway. The first European IPF Patient Summit aims to lead by example. Our programme incorporates research, person-centred care, as well as policy and advocacy tools that can be used to increase the awareness of idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases (ILDs) in Europe. With this Summit, we aim to:

  • Serve as a platform to facilitate interaction among patients, healthcare professionals and industry leaders;
  • Advance meaningful patient involvement in medical congresses;
  • Bring together policy stakeholders to discuss how advocacy and policy efforts can address existing gaps to better respond to patients’ and carers’ needs;
  • Raise awareness of the importance of non-pharmacological treatments for IPF and other ILDs;
  • Inform participants about new therapies and recent scientific developments in the IPF and the ILDs space.

We look forward to welcoming our industry leaders, healthcare professionals, researchers,policy makers and, of course, patients and patient representatives, to  what will be an eventful and innovative summit.

I look forward to seeing you in Warsaw.

Carlos Lines Millán
EU-IPFF President